T1	AdverseReaction 140 166	Hypersensitivity reactions
T2	AdverseReaction 213 225	Pancreatitis
T3	AdverseReaction 272 291	Glucose intolerance
T4	AdverseReaction 338 348	Thrombosis
T5	AdverseReaction 353 363	hemorrhage
T6	AdverseReaction 496 521	systemic hypersensitivity
T7	AdverseReaction 523 536	hyperglycemia
T8	AdverseReaction 538 560	transaminases abnormal
T9	AdverseReaction 562 567	fever
T10	AdverseReaction 569 581	pancreatitis
T11	AdverseReaction 583 598	local reactions
T12	AdverseReaction 600 608	vomiting
T13	AdverseReaction 610 616	nausea
T14	AdverseReaction 618 628	thrombosis
T15	AdverseReaction 630 648	hyperbilirubinemia
T16	AdverseReaction 650 664	abdominal pain
T17	AdverseReaction 650 659;665 675	abdominal pain/discomfort
T18	AdverseReaction 681 689	diarrhea
T19	AdverseReaction 769 794	systemic hypersensitivity
T20	AdverseReaction 796 809	hyperglycemia
T21	AdverseReaction 811 833	transaminases abnormal
T22	AdverseReaction 835 840	fever
T23	AdverseReaction 842 854	pancreatitis
T24	AdverseReaction 856 871	local reactions
T25	AdverseReaction 873 881	vomiting
T26	AdverseReaction 883 889	nausea
T27	AdverseReaction 891 901	thrombosis
T28	AdverseReaction 903 921	hyperbilirubinemia
T29	AdverseReaction 923 937	abdominal pain
T30	AdverseReaction 923 932;938 948	abdominal pain/discomfort
T31	AdverseReaction 954 962	diarrhea
T32	AdverseReaction 2759 2777	allergic reactions
T33	AdverseReaction 4798 4805	allergy
T34	AdverseReaction 4807 4819	pancreatitis
T35	AdverseReaction 4821 4833	coagulopathy
T36	AdverseReaction 4835 4845	hemorrhage
T37	AdverseReaction 4847 4857	thrombosis
T38	AdverseReaction 4861 4868	infarct
T39	AdverseReaction 4871 4889	hyperbilirubinemia
T40	AdverseReaction 4891 4904	hyperglycemia
T41	AdverseReaction 4906 4920	hyperlipidemia
T42	AdverseReaction 4922 4934	ketoacidosis
T43	AdverseReaction 4940 4950	CNS events
T44	AdverseReaction 4940 4943;4952 4962	CNS events (hemorrhage
T45	AdverseReaction 4940 4943;4964 4974	CNS events (hemorrhage, thrombosis
T46	AdverseReaction 4940 4943;4978 4988	CNS events (hemorrhage, thrombosis or infarction
T47	AdverseReaction 4994 5020	cerebral venous thrombosis
T48	Factor 5279 5319	forms specifically requested information
T49	AdverseReaction 5337 5355	allergic reactions
T50	AdverseReaction 5357 5374	thrombotic events
T51	AdverseReaction 5376 5394	hemorrhagic events
T52	AdverseReaction 5396 5419	hepatobiliary disorders
T53	AdverseReaction 5421 5441	pancreatic disorders
T54	AdverseReaction 5447 5460	hyperglycemia
T55	AdverseReaction 6131 6156	hypersensitivity reaction
T56	AdverseReaction 6473 6499	hypersensitivity reactions
T57	Factor 6646 6650	risk
T58	AdverseReaction 6654 6680	hypersensitivity reactions
T59	Severity 7291 7298	Serious
T60	AdverseReaction 7299 7325	hypersensitivity reactions
T61	AdverseReaction 7337 7348	anaphylaxis
T62	Severity 7354 7360	Severe
T63	AdverseReaction 7364 7388	hemorrhagic pancreatitis
T64	AdverseReaction 7376 7388	pancreatitis
T65	AdverseReaction 7402 7421	Glucose intolerance
T66	AdverseReaction 7402 7421	Glucose intolerance
T67	Factor 7422 7425	can
T68	Severity 7459 7471	irreversible
T69	AdverseReaction 7568 7578	Thrombosis
T70	AdverseReaction 7580 7590	hemorrhage
T71	Severity 7679 7686	Grade 3
T72	Severity 7679 7684;7691 7692	Grade 3 and 4
T73	AdverseReaction 7693 7719	hypersensitivity reactions
T74	AdverseReaction 8083 8095	Pancreatitis
T75	AdverseReaction 8864 8883	glucose intolerance
T76	AdverseReaction 8864 8883	glucose intolerance
T77	Severity 8891 8903	irreversible
T78	Severity 9098 9105	Serious
T79	AdverseReaction 9106 9123	thrombotic events
T80	AdverseReaction 9135 9160	sagittal sinus thrombosis
T81	AdverseReaction 9165 9183	pulmonary embolism
T82	AdverseReaction 9284 9304;9310 9319	coagulation proteins were decreased
T83	AdverseReaction 9310 9319;9415 9425	decreased in the majority of patients after a 2-week course of ERWINAZE by intramuscular administration: fibrinogen
T84	AdverseReaction 9310 9319;9427 9445	decreased in the majority of patients after a 2-week course of ERWINAZE by intramuscular administration: fibrinogen, protein C activity
T85	AdverseReaction 9310 9319;9447 9465	decreased in the majority of patients after a 2-week course of ERWINAZE by intramuscular administration: fibrinogen, protein C activity, protein S activity
T86	AdverseReaction 9310 9319;9471 9488	decreased in the majority of patients after a 2-week course of ERWINAZE by intramuscular administration: fibrinogen, protein C activity, protein S activity, and anti-thrombin III
R1	Negated arg1:T49 arg2:T48
R2	Negated arg1:T50 arg2:T48
R3	Negated arg1:T51 arg2:T48
R4	Negated arg1:T52 arg2:T48
R5	Negated arg1:T53 arg2:T48
R6	Negated arg1:T54 arg2:T48
R7	Hypothetical arg1:T58 arg2:T57
R8	Effect arg1:T60 arg2:T59
R9	Effect arg1:T64 arg2:T62
R10	Hypothetical arg1:T65 arg2:T67
R11	Hypothetical arg1:T66 arg2:T67
R12	Effect arg1:T66 arg2:T68
R13	Effect arg1:T73 arg2:T72
R14	Effect arg1:T73 arg2:T71
R15	Effect arg1:T76 arg2:T77
R16	Effect arg1:T79 arg2:T78
N1	Reference T1 meddra:10020751	Hypersensitivity
N2	Reference T2 meddra:10033645	Pancreatitis
N3	Reference T3 meddra:10018429	Glucose tolerance impaired
N4	Reference T4 meddra:10043607	Thrombosis
N5	Reference T5 meddra:10055798	Haemorrhage
N6	Reference T6 meddra:10020751	Hypersensitivity
N7	Reference T7 meddra:10020635	Hyperglycaemia
N8	Reference T8 meddra:10062688	Transaminases abnormal
N9	Reference T9 meddra:10037660	Pyrexia
N10	Reference T11 meddra:10024769	Local reaction
N11	Reference T12 meddra:10047700	Vomiting
N12	Reference T13 meddra:10028813	Nausea
N13	Reference T15 meddra:10020578	Hyperbilirubinaemia
N14	Reference T16 meddra:10000081	Abdominal pain
N15	Reference T17 meddra:10000059	Abdominal discomfort
N16	Reference T18 meddra:10012735	Diarrhoea
N17	Reference T32 meddra:10020751	Hypersensitivity
N18	Reference T33 meddra:10020751	Hypersensitivity
N19	Reference T35 meddra:10009802	Coagulopathy
N20	Reference T38 meddra:10061216	Infarction
N21	Reference T41 meddra:10062060	Hyperlipidaemia
N22	Reference T42 meddra:10023379	Ketoacidosis
N23	Reference T43 meddra:10029202	Nervous system disorder
N24	Reference T44 meddra:10072043	Central nervous system haemorrhage
N25	Reference T45 meddra:10029202	Nervous system disorder
N26	Reference T46 meddra:10029202	Nervous system disorder
N27	Reference T47 meddra:10008138	Cerebral venous thrombosis
N28	Reference T55 meddra:10020751	Hypersensitivity
N29	Reference T61 meddra:10002198	Anaphylactic reaction
N30	Reference T63 meddra:10033650	Pancreatitis haemorrhagic
N31	Reference T50 meddra:10043607	Thrombosis
N32	Reference T80 meddra:10042567	Superior sagittal sinus thrombosis
N33	Reference T81 meddra:10037377	Pulmonary embolism
N34	Reference T82 meddra:10009736	Coagulation factor decreased
N35	Reference T83 meddra:10005520	Blood fibrinogen decreased
N36	Reference T84 meddra:10037005	Protein C decreased
N37	Reference T85 meddra:10051120	Protein S decreased
N38	Reference T86 meddra:10049547	Antithrombin III decreased
